Loading...

SOLARA Solara Active Pharma Sciences Ltd Quarterly Earnings Reports Announcement

Slr

SLR

Solara Active Pharma Sciences Ltd

(SOLARA)

2024 Announcement

Resignation of Director

Volume Movement Clarification

US FDA inspection closure

Earnings Call Transcript

Financial Results Released

Monitoring Agency Report

Q2 FY26 Earnings Call

Management Changes

No Deviation Reported

New CHRO Appointment

Q2 FY26 Results

Director Resignation

Financial Results Release

Investor Call Announced

ESG Rating Update

Compliance Certificate

Share Allotment

Investor Campaign Announcement

Volume Movement Clarification

AGM Notice Published

Annual General Meeting

100 Days Campaign

Call Money Received

Monitoring Agency Report

Earnings Call Transcript

Financial Results Published

Investor Meet Recording

Q1 2026 Results

Funds Utilization Update

Investor Call Scheduled

SEBI Compliance Certificate

Fractional Shares Reminder

First Call Money Reminder

First Call Reminder

Credit Rating Update

Share Transfer Notice

Annual Compliance Report

Earnings Call Transcript

Financial Results Published

Quarterly Earnings Call

Appointment of Auditors

Management Appointment

Management Retirement

Management Change

No Deviation Reported

Q4 FY25 Results

FDA Inspection Passed

Investor Conference Call

Monitoring Agency Report

Office Address Change

Office Address Change

New Subsidiary Incorporated

Compliance Certificate

Newspaper Publication

First Call Money Notice

Rights Issue Update

Rights Issue Call

Postal Ballot Notice

Subsidiary Closure

Management Resignation

Management Changes

Management Change

Monitoring Agency Report

New Subsidiary Approval

Earnings Call Transcript

Financial Results Published

Earnings Call Audio

Q3 FY25 Results

No Deviations Reported

Board Meeting Update

Investor Call Scheduled

Compliance Certificate

Monitoring Agency Report

Earnings Call Transcript

Financial Results

Funds Utilization Report

Earnings Call Update

Compliance Certificate

Conference Call Scheduled

Annual General Meeting

AGM Announcement

Completion of EU-GMP Inspec...

Resignation of Director

Monitoring Agency Report

Financial Results Publication

Earnings Call Outcome

Deviation Statement

ESOP Plan Introduction

Certificate Submission

Conference Call

Newspaper Advertisement

Allotment Details

Rights Issue Closure

Financial Results Announcement

Compliance Report Submission

Advertisement Publication

Conference Call

FDA Inspection Success

Rights Issue Terms Finalized

Certificate Submission

Update on Shareholding Tran...

Price Movement Clarification

Compliance Certificate Subm...

Certification Submission

Divestment Update

Appointment Of CFO

Management Change

Advertisement - Unaudited F...

Audio recordings of Q3 FY24...

Management Changes

Resignation and Appointment

Conference Call

Certificate Submission

Postal Ballot Notice

Management Change

Change in Designation

Online Dispute Resolution M...

Earnings Call Transcript

Financial Results - Newspap...

Land & Building Sale

Appointment of Directors

Conference Call

Fire Incident Update

CFO Appointment

Certificate under Reg. 74 (...

Financial Statements

Financial Statements

Analyst Questions

Committee Reconstitution

Conference Call

Financial Statements

Completion of Inspection

Conference Call

Appointments, Resignations

Investor Meetings

Appointments, Resignations

Equity Offerings

Management Changes

Equity Offerings

Annual compliance report

Earnings Call Transcript

Financial Statements Public...

Conference Call

External Links:

Data:

Solara Active Pharma Sciences Ltd confirmed there was no deviation in the utilization of funds raised through a Rights Issue amounting to ₹157.48 crores for the quarter ended September 30, 2024. The funds were used as originally planned, primarily for debt repayment of ₹118.61 crores.

AI Assistant

Solara Active Pharma Sciences Ltd

2024

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.